ESC 365 - Sacubitril/valsartan promotes cardiac reverse remodeling and preserves renal function in a real-world heart failure and reduced ejection fraction (HFrEF) population

EACVI Premium Access

Sacubitril/valsartan promotes cardiac reverse remodeling and preserves renal function in a real-world heart failure and reduced ejection fraction (HFrEF) population

Session: Imaging: heart failure

Topic: Imaging of Heart Failure

Event: EuroEcho 2019

Congress Presentation

Add to my library

9 more presentations in this session

Panel of experts:.

The relationship between right ventricle-arterial coupling and cardiac metabolism in pulmonary arterial hypertension - multimodal study.

Speaker: Doctor R. Kazimierczyk (Bialystok, PL)

Left atrial pump function assessed by speckle tracking echocardiography adds important value for the diagnosis of heart failure with preserved ejection fraction

Speaker: Associate Professor R. Rimbas (Bucharest, RO)

Early cardiac reverse remodeling in a large cohort of patients with HFrEF treated with Sacubitril/Valsartan

Recompensation induces distinct changes in myocardial work in patients with acutely decompensated heart failure and reduced vs preserved left ventricular ejection fraction

Speaker: Doctor C. Morbach (Wuerzburg, DE)

Access the full session

Imaging: heart failure

Speakers: Doctor R. Kazimierczyk, Associate Professor R. Rimbas, Doctor C. Morbach

About the event

EuroEcho 2019

4 December - 7 December 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources